X

Drug Profile

ET 600

Alternative Names: ET-600

Latest Information Update: 16 Aug 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tulex Pharmaceuticals
Developer Eton Pharmaceuticals
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Clinical Phase Unknown Diabetes insipidus

Most Recent Events

08 Aug 2024 Eton Pharmaceuticals plans a Bioequivalence study for Diabetes insipidus in Q3 of 2024
19 Apr 2024 Eton Pharmaceuticals announces intention to submit NDA for Diabetes insipidus in the first quarter of 2025
19 Apr 2024 Eton Pharmaceuticals plans to launch ET 600 in Diabetes insipidus in early 2026

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com